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Abstract
Background: Cardiac syndrome X is an important therapeutic and diagnostic challenge to physician. Study of Csx
patients may help to understand the pathophysiology of coronary microcirculation and to gain an insight on the
management of these group patients.
Methods: We measured the flow mediated dilation of the brachial artery both endothelium dependent and
independent vasodilatation by high resolution ultrasound in 30 cardiac syndrome X patients and matched with 30
healthy control subjects.
Results: Significantly decreased flow mediated dilatation was observed in patients when compared to control (9.42
± 7.20 vs 21.11 ± 9.16 p < 0.01) but no significant difference was observed between groups in response to
nitroglycerin (25.39 ± 6.82 vs 28.87 ± 8.69). Receiver operator characteristic analysis showed that value of < 11.11
had sensitivity of 80%, specificity 86.67%, positive predictive value 76.66%, negative predictive value 83.33%. In
total, 46% of subjects had endothelial dysfunction and of them, CSX subjects had higher prevalence (76% vs 16% p
< 0.01) than control subjects. Higher mean values of body mass index, systolic blood pressure and diastolic blood
pressure was observed in subjects with FMD < 11.11 than > 11.11(p < 0.01). In logistic regression analysis, FMD
was significantly associated with systolic blood pressure (Odds ratio 1.122 95% CI 1.053-1.196 p < 0.01) and body
mass index (Odds 1.248 95%CI 0.995-1.56 p < 0.05).
Conclusions: The study suggests impairment of endothelial function in cardiac syndrome X patients. Increased
Systolic blood pressure and body mass index may increase the risk of impairment of endothelial function in this
group of patients.
Introduction
Cardiac syndrome X (Csx) is defined by the presence of
angina-like chest pain, a positive response to stress test-
ing and angiographically normal coronary arteries [1]
Csx represent a heterogeneous entity in terms of clini-
cally and pathophysiologically [2], interesting because
around 20% of the patients with angina chest pain
undergoing coronary angiography have normal coronary
arteries [3] and pose an important diagnostic and thera-
peutic challenges to the physicians. Study of CSX
patients may help to understand the pathophysiology of
coronary microcirculation and cardiac pain [4]
Microvascular dysfunction has been observed in CSX
patients [5,6]
In the absence of established mechanism, multiple
pathogenic mechanisms have been proposed for Csx
includes: abnormal coronary flow reserve, insulin resis-
tance, abnormal autonomic control, enhanced sodium-
hydrogen exchange activity, abnormal cardiac sensitivity,
microvascular spasm, extracardiac causes, psychological
abnormalities, myocardial ischemia and abnormal pain
perception [2,7]. Evaluation of endothelial function has
prognostic value [8] Endothelial function assessment is
useful in identifying early atherosclerosis changes and the
detection of the severity as well [9]. Given the central
role of the endothelium in the development and clinical
course of atherosclerosis, endothelial function testing
may serve as a useful biomarker of atherosclerosis [10].
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Interventions that improve endothelial function also
decrease cardiovascular events [11]. Vessel function may
play a very important role in determining cardiovascular
risk, over and above the risk conveyed by a structural
impediment to flow such as a large plaque [12] In this
study, we have made an attempt to evaluate the endothe-
lial function in brachial artery of CSX patients using high
resolution B-mode ultrasound and to correlate with cor-
onary risk factors.
Materials and methods
In this study, 30 patients with history of angina like
chest pain, reported positive on tread mill test and with
normal coronaries on coronary angiography, were diag-
nosed as Csx patients. Thirty age matched subjects, who
were diagnosed healthy based on ECG and echocardio-
gram were treated as control. Informed consent was
obtained from each of the patients and health controls
following ethical guidelines of the 1975 Declaration of
Helsinki. This study was approved by Institutional Ethics
Committee of Sri Venkateswara Institute of Medical
Sciences, Tirupti, Andhra Pradesh, India. The age of
both groups of subjects ranged from 40-60 years. There
were 20 male and 10 female in CSx; and 17 male and
13 female subjects in control group. Details of age, his-
tory of hypertension, ischemic heart disease, type 2 dia-
betes and smoking were enquired. Subjects were
examined clinically for pulse, blood pressure, respiratory,
cardiovascular and central nervous system followed by
ECG and Echocardiogram evaluation. Height and weight
were measured. Body mass index was calculated.
Blood samples were drawn after 12 hr fasting. The
samples were assayed for glucose, total cholesterol, tri-
glyceride, HDL cholesterol, blood urea and creatinine.
LDL cholesterol was calculated as per Fridewald et al
[13]. Endothelial function of subjects was evaluated by
Doppler study on right brachial artery following Celer-
majer et al [14]. The subjects were requested to abstain
from alcohol, caffeine and smoking for 8 hours before
attending the procedure. The procedure was performed
by 7.5 MHZ linear array tranducer with image point HX
using Ultra sound equipment of Agilent technology,
India. Scans of subjects were obtained at rest, during
reactive hyperemia and again at rest.
The subjects were asked to lie quietly for at least 10
min before the first scan. The brachial artery was
scanned in longitudinal section 2 cm above the elbow,
and the center of the artery was identified when the
clearest picture of the anterior and posterior intimal
layers were obtained. The transmit zone was set to the
depth of the near wall, because of the greater difficulty
in evaluating the “M” line (the interface between the
media and adventia) of the near wall as compared with
that of the far wall. Depth and gain settings were set to
optimize images of interface between the lumen and the
arterial wall, and the obtained images were magnified.
Settings for operating the machine were not changed
during the study.
When a satisfactory transducer position was found, the
skin was marked and the arm was kept in the same posi-
tion throughout the study. A resting scan was obtained.
The arterial diameter was measured. Increased flow was
induced by the inflation of a sphygmomanometer cuff
placed around the forearm (distal to the scanned part of
the artery) at a pressure of 200 mmHg for 4.5 min, fol-
lowed by release. A second scan was performed 90 s after
deflation of the cuff. The diameter of the artery was mea-
sured at the peak of R wave (corresponding to end dia-
stole). Flow-mediated dilation was calculated. Average of
three observations was recorded. Flow-mediated dilatation
was presented as the percent change from baseline to
hyperemia. Fifteen minutes were allowed for vessel recov-
ery and then a further resting scan was taken. After that
sublingual glyceryl trinitrate (GTN-200 mics/puff) was
administered and ten minutes later, the last scan was
done. ECG was monitored through the scans and the
artery diameter was measured at the peak of R wave (cor-
responding to end diastole). An average of 3 values was
taken for each measurement. FMD (flow mediated vasodi-
latation) and NMD (nitrate mediated vasodilatation) in
syndrome X was compared with the data of healthy con-
trol subjects. FMD was calculated using the formula FMD
= (d2-d1) × 100/d1. Where d1 is the brachial artery dia-
meter at baseline, d2 is brachial artery diameter after 90
seconds of cuff release. Changes in the diameter after both
interventions i.e. after stress and GTN, was expressed as
percentage change from the pre-treatment value.
Statistical analysis
Means were compared with student ‘t” test and categori-
cal variables with chi-square. Logistic regression was
done to find the relation between dependent and inde-
pendent variables. FMD Cutt-off values were determined
using receiver operator curve analysis.
Results
Higher mean systolic, diastolic blood pressure and lower
glucose and % FMD were observed in Csx patients
when compared to the control subjects (p < 0.01).
Lower mean % of FMD was observed in male than
female subjects (12.35 ± 7.73 vs. 19.96 ± 11.71p < 0.01).
Lower mean % of FMD with increasing BMI was
observed in both cases and control (in cases; BMI < 25
13.68 ± 6.58 vs. 6.58 p < 0.00; control: 23.68 ± 9.09 vs
15. 97 ± 7.19 p < 0.00) subjects (Table 1).
Higher mean body mass index, systolic blood pressure
and diastolic blood pressure was observed in FMD <
11.11 when compared to FMD > 11.11(p < 0.01) (table 2).
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To determine the sensitivity and specificity of FMD
cut-off value in this population, we have performed
receiver operator characteristic analysis (ROC). In
ROC analysis (Figure 1), we have found that FMD
< 11.1 had sensitivity, specificity, positive predictive
value and negative predictive values in the following
percentage 80%, 86.67%, 76.66% and 83.33% respec-
tively (Figure 1).
In subjects with CSX, 77% had endothelial dysfunction
as indicated by FMD < 11.1 as against 17% in control
group (p < 0.01). When assessed in logistic regression
analysis, FMD was significantly associated with Csx
(Odds ratio 16.42 95% CI 4.569-59.07 p < 0.001).
A logistic regression analysis was done to find out the
factors contributing to the microvascular dysfunction in
Csx and found that systolic blood pressure (Odds ratio
1.122 95% CI 1.053-1.196 p < 0.01) and body mass
index (Odds 1.248 95%CI 0.995-1.56 p < 0.05) were sig-
nificantly associated.
Discussion
Endothelium is the monolayer of endothelilal cells lining
the lumen of blood vessels [10]. It maintains a balance
between vasoactive and vasodilator susbstances and the
loss of this function leads to endothelial dysfunction.
Insight into the function of endothelium has led to the
development of tests for its assessment. All of these tests
are based on the vasomotor response of endothelium to
vasoactive stimuli. Intracoronary doppler techniques
have disadvantages like invasive nature, expensive, rela-
tively inaccessibility, risks inherent with coronary artery,
difficulty in extending to larger studies and understand-
ing microvascular pathophysiology and failure to repre-
sent true changes in conduit arteries predisposed to
atherosclerosis [15,16]. The drawbacks associated with
plethysmography are reproducibility, invasive nature, risk
of median nerve injury, infection and vascular injury [17].
Vascular tonometry and measurement of vascular stiff-
ness are limited by influence of structural aspects of the
vasculature beyond the endothelium.
Non-invasive ultrasound test is based on the measure-
ment of changes in brachial artery diameter in response
Table 1 Clinical characteristics of the subjects
Variables CSX(n = 30) Control(n = 30)
Age (years) 48.76 ± 6.57 47.70 ± 6.79
Body mass index 27.52 ± 5.79 24.35 ± 3.09*
Systolic blood pressure (mmHg) 144.73 ± 12.10 114.00 ± 8.94*
Diastolic blood pressure (mmHg) 93.80 ± 9.88 74.86 ± 5.39*
Glucose (mg/dl) 75.70 ± 21.31 88.40 ± 21.38*
Total Cholesterol (mg/dl) 179.00 ± 15.52 174.73 ± 20.58
Triglycerides (mg/dl) 131.66 ± 39.80 138.16 ± 40.86
HDL cholesterol (mg/dl) 43.70 ± 8.26 42.26 ± 7.01
LDL cholesterol (mg/dl) 113.16 ± 18.51 107 ± 21.12
VLDL cholesterol (mg/dl) 26.26 ± 7.82 25.56 ± 7.53
Serum Creatinine (mg/dl) 0.88 ± 0.20 0.84 ± 0.17
Blood urea(mg/dl) 22.80 ± 7.43 22.50 ± 6.31
Mean % of FMD 9.42 ± 7.20 21.11 ± 9.16*
Mean % NMD 25.39 ± 6.82 28.87 ± 8.69
*p < 0.01
Table 2 Clinical characteristics of the subjects with
respect to FMD




Age (years) 49.21 ± 6.18 47.37 ± 7.01
Body mass index 28.44 ± 5.51 23.74 ± 2.84*
Systolic blood pressure
(mmHg)
143.28 ± 15.30 117.18 ± 11.70*
Diastolic blood pressure
(mmHg)
92.92 ± 10.46 76.81 ± 8.46*
Glucose (mg/dl) 77.78 ± 21.31 85.78 ± 22.45
Total Cholesterol (mg/dl) 176.96 ± 15.27 176.78 ± 20.67
Triglycerides (mg/dl) 134.21 ± 36.79 135.53 ± 43.41
HDL cholesterol (mg/dl) 42.60 ± 8.10 43.31 ± 7.31
LDL cholesterol (mg/dl) 113.00 ± 18.71 107.56 ± 20.91
VLDL cholesterol (mg/dl) 26.10 ± 7.10 25.75 ± 8.16
Serum Creatinine (mg/dl) 0.89 ± 0.20 0.84 ± 0.17
Blood urea(mg/dl) 22.21 ± 7.30 23.03 ± 6.50
*p < 0.01
FMD













Figure 1 Receiver operator characteristic (ROC) curve for FMD
values. Area under the curve (AUC) = 0.874 95% CI 0.763-0.946
(p < 0.0001)
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to reactive hyperemia and is considered as a gold stan-
dard for clinical studies on conduit artery endothelial
biology [18]. It is repeatable and reproducible, reflects
important biology, has some data to support its predict-
ability and is useful in serial studies of disease reversi-
bility [12]. Brachial artery endothelium-dependent
dilatation was found to be correlated with coronary cir-
culation in the same patient [12,19]. A single measure-
ment of endothelial function in both the coronary and
peripheral circulation can be of prognostic value in
both normal and coronary heart disease patients
[16,20,21].
Several studies have observed lower flow mediated
dilation in CSX patients when compared to healthy con-
trols [22-26] but few studies [24-26] observed no differ-
ence in endothelium independent vasodilatation. In the
present study also, we have observed lower endothelium
dependent flow mediated dilation in CSX patients when
compared to the healthy control (p < 0.01). In case of
glyceryl nitrite dependent dilation, no such difference
was observed in our observation. It appears that
endothelium dependent vascular dysfunction in CSX
group of patients, is probably a generalized phenomenon
as observed earlier [27].
Elevated levels of total cholesterol, LDL cholesterol,
apolipoprotein B100, Lp(a), aortic and fractional pulse,
platelet volume, nocturnal melatonin levels, CRP, reac-
tive oxygen species and hydroperoxides and decreased
oestrogen were observed in CSX patients [2,24,28-32].
In the present study, higher mean levels of body mass
index, systolic and diastolic blood pressure was observed
in CSX patients when compared to the control group.
An area under curve for cut-off value of 11.1 showed
a value of 0.874 indicating that ultrasound is useful tool
for identifying endothelial impairment in Csx patients
and able to predict the impairment in 86% of subjects as
shown by specificity of the cut-off value. This cut-off
value is observed in a cross-sectional study and has to
be established in longitudinal study involving larger
sample size. To the best of our knowledge, no study in
India reported cutt-off value for flow mediated dilation
in Csx patients and this study attempts to propose the
cut-off value for flow-mediated dilatation in Indian
population. We have assessed the endothelial function
manually using hand held probe and this is the limita-
tion of the study.
In the present study, higher mean body mass index,
systolic and diastolic blood pressure in FMD < 11.11
than FMD > 11.11 group (p < 0.01) was observed. Sys-
tolic blood pressure and body mass index significantly
associated with impairment of endothelial function. A
5.77 fold increase in the incidence of hypertension in
the lowest than highest FMD quartile was observed
over a follow up of 3.5 years in risk factor free post
menopausal women [33]. A specific endothelial NO
abnormality in microcirculation and conductance ves-
sels of hypertensive subjects has been confirmed in
multiple well controlled clinical investiagations [34].
Increase in systemic blood pressure in normotenisve
subjects after intravenous infusion of nitric oxide
synthase antagonists was observed [35]. Higher blood
pressure in endothelial nitric oxide synthase knock
out when compared to normal mice, more nitric
oxide synthase 3 gene mutations in hypertnsive sub-
jects also established impaired endothelial function
[34].
Lower FMD was observed with increase in BMI
[36,37]. Nuclear Factor B Activation contributes to vas-
cular endothelial dysfunction via oxidative stress in
overweight/obese middle-aged and older humans [38].
Modest weight loss can improve endothelial function
and affect the entire cluster of coronary heart disease
risk factors simultaneously [39].
The results of the present study showed higher preva-
lence of microvascular dysfunction (78%) in the CSx
patients when compared to the control subjects and
suggest that early detection and management of systolic
blood pressure and encouraging weight loss may be
helpful in the management of CSX.
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